Mode
Text Size
Log in / Sign up
Phase 3 N=102 Randomized Double-blind Basic Science

Periodontal Infection and Endothelial Dysfunction

Periodontitis

Enrolled (actual)
102
Serious AEs
1.0%
Results posted
Apr 2014
Primary outcome: Primary: Brachial Artery Flow-mediated Dilation — 10.2; 10.3; 13.1; 8.1 Percentage of dilatation of brachial art — p=0.98

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
One-Stage Full-Mouth Disinfection (Procedure); Periodontal care (Procedure)
Age
Adult, Older Adult · 25+ yrs
Sex
All
Sponsor
Universidad del Valle, Colombia
Primary completion
Mar 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Brachial Artery Flow-mediated Dilation
10.2; 10.3; 13.1; 8.1; 11.2; 9.7 0.98
SECONDARY
High-sensitivity C-Reactive Protein
4.2; 3.1; 4.9; 4.1; 3.3; 3.2
SECONDARY
Total Cholesterol
197; 192.4; 195.4; 186.9; 203.9; 200.6
SECONDARY
White Blood Cell Count
6937; 6380; 6198; 6088; 5464; 5382
SECONDARY
Subgingival Microbiota
31; 42; 31; 38; 34; 40
SECONDARY
LDL Cholesterol
113.1; 106.4; 111.3; 104.6; 119.9; 109.5
SECONDARY
Endothelial Leukocyte Adhesion Molecule-1 (E-Selectin)
44.8; 42.9
SECONDARY
Intercellular Adhesion Molecule 1 (ICAM-1)
247.1; 235.4
SECONDARY
Vascular Cell Adhesion Molecule 1 (VCAM-1)
1601.6; 1588.1
SECONDARY
Myeloperoxidase (MPO)
62.6; 83.8
SECONDARY
Matrix Metalloproteinase-9 (MMP-9)
103.4; 110.5
SECONDARY
Tissue Plasminogen Activator Inhibitor-1 (tPAI-1)
116.1; 110.7

Summary

The purpose of this study is to determine the effect of periodontal therapy on endothelial function and other biomarkers of cardiovascular disease

Eligibility Criteria

Inclusion Criteria

  • Subjects must be 25 years of age or older
  • Three or more periodontal pockets with a probing depth (PD) > 5mm
  • Have at least 20 natural teeth
  • Provide informed consent and willingness to cooperate with the study protocol

Exclusion Criteria

  • History of antibiotic use in the previous three months
  • Pregnant or lactating females
  • Treatment with antihypertensive, antilipemic, antiarrhythmic, and other cardiovascular drugs
  • Systemic diseases such as diabetes, HIV/AIDS, liver disease, chronic renal failure, tuberculosis, and autoimmune diseases
  • Previous history of cardiovascular disease: Acute myocardial infarct, stable angina, unstable angina, heart failure, atrial fibrillation, atrioventricular block, peripheral vascular disease, cerebrovascular accident
  • Patients who received periodontal treatment within the last 3 months
  • Patients who require antibiotic prophylaxis before examination or treatment
  • Patients with mental retardation and dementia
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00681564). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search